STOK · Insider Trading
Stoke Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by STOK officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-04 | Barry Ticho | CHIEF MEDICAL OFFICER | Sell | −7,195 | −$189.91K |
| 2026-10-02 | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sell | −627 | −$16.51K |
| 2026-10-02 | Barry Ticho | CHIEF MEDICAL OFFICER | Sell | −1,051 | −$27.49K |
| 2026-09-25 | Alexander Cumbo | Director | A | +39,674 deriv. | — |
| 2026-09-03 | Barry Ticho | CHIEF MEDICAL OFFICER | Sell | −5,545 | −$170.06K |
| 2026-08-18 | Edward M. MD Kaye | Director | MIXED | +13,683 | −$402.53K |
| 2026-08-18 | Barry Ticho | CHIEF MEDICAL OFFICER | MIXED | +5,233 | −$152.69K |
| 2026-08-18 | Jonathan Allan | GENERAL COUNSEL & CORP SEC | MIXED | +3,139 | −$91.64K |
| 2026-08-05 | Barry Ticho | CHIEF MEDICAL OFFICER | Sell | −7,176 | −$208.39K |
| 2026-07-17 | Thomas McCauley | Chief Scientific Officer | A | +225,000 deriv. | — |
| 2026-07-17 | Seth Loring Harrison | Director | G | — | — |
| 2026-07-06 | Barry Ticho | CHIEF MEDICAL OFFICER | Sell | −7,228 | −$236.07K |
| 2026-06-18 | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sell | −1,457 | −$43.64K |
| 2026-06-05 | Jennifer Burstein | Director | A | +17,786 deriv. | — |
| 2026-06-05 | Edward M. MD Kaye | Director | A | +17,786 deriv. | — |
| 2026-06-05 | Seth Loring Harrison | Director | A | +17,786 deriv. | — |
| 2026-06-05 | Arthur Tzianabos | Director | A | +17,786 deriv. | — |
| 2026-06-05 | Julie Smith | Director | A | +17,786 deriv. | — |
| 2026-06-05 | Adrian R. Krainer | Director | A | +17,786 deriv. | — |
| 2026-06-05 | Arthur A Levin | Director | A | +17,786 deriv. | — |
| 2026-06-03 | Barry Ticho | CHIEF MEDICAL OFFICER | Sell | −1,795 | −$54.89K |
| 2026-05-05 | Barry Ticho | CHIEF MEDICAL OFFICER | Sell | −2,243 | −$73.55K |
| 2026-04-07 | Clare Kahn | Director | A | +30,782 deriv. | — |
| 2026-04-03 | Barry Ticho | CHIEF MEDICAL OFFICER | Sell | −1,838 | −$60.03K |
| 2026-03-24 | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sell | −9,293 | −$313.04K |
| 2026-03-19 | Jason Hoitt | Chief Patient Officer | Sell | −3,712 | −$119.31K |
| 2026-03-19 | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sell | −8,895 | −$285.90K |
| 2026-03-19 | Thomas Leggett | Chief Financial Officer | Sell | −4,578 | −$147.14K |
| 2026-03-19 | Barry Ticho | CHIEF MEDICAL OFFICER | MIXED | −12,946 | −$453.85K |
| 2026-03-17 | Thomas Leggett | Chief Financial Officer | M | +14,750 | — |
| 2026-03-17 | Arthur A Levin | Director | Sell | −605 | −$22.26K |
| 2026-03-17 | Jonathan Allan | GENERAL COUNSEL & CORP SEC | M | +25,475 | — |
| 2026-03-17 | Jason Hoitt | Chief Patient Officer | M | +10,000 | — |
| 2026-03-17 | Edward M. MD Kaye | Director | M | +61,750 | — |
| 2026-03-17 | Barry Ticho | CHIEF MEDICAL OFFICER | M | +33,850 | — |
| 2026-03-12 | Adrian R. Krainer | Director | Sell | −33,243 | −$1.32M |
| 2026-03-12 | Arthur Tzianabos | Interim Executive Chair | MIXED | −400 | −$141.27K |
| 2026-03-04 | Adrian R. Krainer | Director | Sell | −7,229 | −$286.72K |
| 2026-02-19 | Jason Hoitt | Chief Patient Officer | A | +120,000 deriv. | — |
| 2026-02-19 | Ian F Smith | Chief Executive Officer | A | +322,000 deriv. | — |
| 2026-02-19 | Barry Ticho | CHIEF MEDICAL OFFICER | A | +100,000 deriv. | — |
| 2026-02-19 | Thomas Leggett | Chief Financial Officer | A | +100,000 deriv. | — |
| 2026-02-19 | Jonathan Allan | GENERAL COUNSEL & CORP SEC | A | +88,000 deriv. | — |
| 2026-01-05 | Arthur A Levin | Director | M | +1,211 | — |
| 2025-12-10 | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sell | −3,978 | −$128.41K |
| 2025-12-10 | Edward M. MD Kaye | Director | Sell | −13,430 | −$433.39K |
| 2025-12-05 | Jonathan Allan | GENERAL COUNSEL & CORP SEC | MIXED | −3,803 | −$306.32K |
| 2025-12-05 | Edward M. MD Kaye | Director | MIXED | +11,249 | −$466.96K |
| 2025-12-05 | Barry Ticho | CHIEF MEDICAL OFFICER | MIXED | +4,642 | −$167.12K |
| 2025-12-03 | Barry Ticho | CHIEF MEDICAL OFFICER | MIXED | +7,961 | −$121.47K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Seth Loring Harrison | Director | 17,161,713 | $476.07M |
| Montrago Trustees Ltd | 10%+ Owner | 3,906,181 | $108.36M |
| Adrian R. Krainer | Director | 283,302 | $7.86M |
| Edward M. MD Kaye | Director | 124,557 | $3.46M |
| Arthur Tzianabos | Interim Executive Chair | 35,694 | $990.15K |
| Arthur A Levin | Director | 22,216 | $616.27K |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | 20,598 | $571.39K |
| Thomas Leggett | Chief Financial Officer | 13,476 | $373.82K |
| Jason Hoitt | Chief Patient Officer | 12,207 | $338.62K |
| Barry Ticho | CHIEF MEDICAL OFFICER | 11,864 | $329.11K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the STOK quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.